To mark Blood Cancer Awareness Month, today Novartis UK and the dedicated UK charity MPN Voice are launching a new AR experience and art installation at Westfield White City. “Meet the MPN10″ is a bespoke art installation that depicts the 10 key symptoms of Myeloproliferative neoplasms (MPNs) which have been brought to life today on […]
image: Innovative optical technologies for non-invasive microscopy allowed the research team to reveal the overproduction of lipid droplets, the mitochondrial network rearrangement and the morphological reshaping as first early indicators of therapy-induced senescence in human tumoral cells that underwent anticancer treatments. view more Credit: Politecnico di Milano Milan, September 13th, 2023. A new scientific study published […]
Courtney DiNardo, MD, MSCE, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine (Vidarza) and venetoclax (Venclexta) doublet therapy in select patients with acute myeloid leukemia (AML). There is significant unmet need for patients with FLT3-ITD […]
Stephen M. Ansell, MD, PhD, professor of medicine, interim chair, Department of Oncology, chair, consultant, Division of Hematology, Department of Internal Medicine, chair, Faculty Development and Recruitment, Mayo Clinic, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes. Immunotherapy continues to revolutionize the treatment of […]
Innovative optical technologies for non-invasive microscopy allowed the research team to reveal the overproduction of lipid droplets, the mitochondrial network rearrangement and the morphological reshaping as first early indicators of therapy-induced senescence in human tumoral cells that underwent anticancer treatments. Credit: Politecnico di Milano A new study published in Science Advances has investigated one of […]
Claire Harrison, MD, FRCP, FRCPath The National Institute for Health and Care Excellence (NICE) has published its Final Draft Guidance recommending the use of ruxolitinib (Jakafi) as treatment for eligible patients in England and Wales with polycythemia vera (PV) that is resistant or intolerant to hydroxycarbamide/hydroxyurea (HC/HU).1 “There is a significant unmet need for people […]
Blood Cancer © stock.adobe.com The Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has accepted the new drug application (NDA) seeking the approval of golidocitinib (AZD4205) for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).1 The application was supported by data from part B of the phase 1/2 JACKPOT8 trial […]
Some time ago, a woman with breast cancer gave her doctor — oncologist Cristina Saura — some samples of her breast milk, which she had frozen 18 months before the diagnosis. The tumor was detected when she was pregnant with her third child. The woman feared she had transmitted the disease through breast milk to […]
